Tango Therapeutics, Inc.

NASDAQ:TNGX

Biotechnology

Healthcare
$22.71 -10.03%

-$3.24 today

Market cap
$3.85B
Beta
1.19
P/E (TTM)
-38.9
EPS (TTM)
-$0.75
52W Low $4.60High $34.39

Volume 1.81M

Average 3.67M

Income Statement

Follow revenue through to earnings.

Revenue

$62.38M

FY 2025 · Annual

+48.3% YoY

Operating Income

-$111.29M

FY 2025 · Annual

Net Income

-$101.59M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue37.04M24.86M36.53M42.07M62.38M
Cost of Revenue00002.28M
Gross Profit37.04M24.86M36.53M42.07M60.1M
Gross Margin100.0%100.0%100.0%100.0%96.3%
Research & Development77.64M105.91M115.2M143.92M132.17M
Selling, General & Admin17.6M30.03M35.5M43.75M41.51M
Operating Expenses95.23M135.93M150.7M187.66M171.39M
Depreciation & Amortization897K1.61M2.42M2.5M2.28M
EBITDA(57.05M)(106.51M)(99.2M)(127.6M)(99.31M)
EBITDA Margin-154.0%-428.5%-271.6%-303.3%-159.2%
Operating Income(58.19M)(111.07M)(114.17M)(145.6M)(111.29M)
Operating Margin-157.1%-446.8%-312.6%-346.1%-178.4%
Interest Income495K1.46M6.62M7.89M5.63M
Interest Expense00000
Other Income / Expenses247K2.95M12.56M15.5M9.7M
Income Before Tax(57.94M)(108.12M)(101.61M)(130.09M)(101.59M)
Pre-Tax Margin-156.4%-434.9%-278.2%-309.2%-162.8%
Income Tax Expense292K54K134K208K4K
Net Income(58.24M)(108.18M)(101.74M)(130.3M)(101.59M)
Net Margin-157.2%-435.1%-278.5%-309.7%-162.9%
EPS (Basic)(0.94)(1.23)(1.08)(1.19)(0.87)
EPS (Diluted)(0.94)(1.23)(1.08)(1.19)(0.87)
Weighted Avg Shares62.11M87.82M94.57M109.23M116.17M
Weighted Avg Shares (Diluted)62.11M87.82M94.57M109.23M116.17M

TNGX Earnings Waterfall · TTM

NASDAQ:TNGX · Revenue to Net Income

Key Ratios

EPS$-1.38
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-15.2
P/S Ratio0.0

Analysis

$0 of revenue converted into -$208.0M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.38, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 13, 2026
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 9, 2026
SC 13G/ASC 13G/A filingNov 6, 2026
4Statement of changes in beneficial ownershipNov 4, 2026

How much revenue does TNGX generate?

Tango Therapeutics, Inc. (TNGX) reported $62.38M of revenue in fiscal 2025.

Is TNGX profitable?

Tango Therapeutics, Inc. (TNGX) reported -$101.59M of net income, with a net margin of -162.9%.